TScan Therapeutics Announces Board and Executive Changes
Ticker: TCRX · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1783328
| Field | Detail |
|---|---|
| Company | Tscan Therapeutics, Inc. (TCRX) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
TScan Therapeutics shakes up its board and exec pay structure as of Aug 14, 2025.
AI Summary
TScan Therapeutics, Inc. announced on August 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Numbers
- 001-40603 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-5282075 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Registrant
- August 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 830 Winter Street Waltham, Massachusetts 02451 (address) — Principal executive offices
FAQ
What specific roles have been affected by the departure of directors or officers?
The filing indicates the departure of 'certain officers' and 'directors' but does not specify individual names or roles in this section.
Who are the newly elected directors?
The filing states that directors have been elected but does not name the individuals in this excerpt.
What are the key changes in compensatory arrangements for officers?
The filing notes changes to 'Compensatory Arrangements of Certain Officers' but does not provide specific details on the nature of these changes.
What is the exact date of the reported events?
The date of the earliest event reported is August 14, 2025.
Where are TScan Therapeutics' principal executive offices located?
The principal executive offices are located at 830 Winter Street, Waltham, Massachusetts 02451.
Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2025-08-20 16:10:34
Key Financial Figures
- $0.0001 — istered Voting Common Stock, par value $0.0001 per share TCRX The Nasdaq Global Ma
Filing Documents
- d55649d8k.htm (8-K) — 25KB
- 0001193125-25-184083.txt ( ) — 137KB
- tcrx-20250814.xsd (EX-101.SCH) — 3KB
- tcrx-20250814_lab.xml (EX-101.LAB) — 18KB
- tcrx-20250814_pre.xml (EX-101.PRE) — 11KB
- d55649d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TScan Therapeutics, Inc. Date: August 20, 2025 By: /s/ Gavin MacBeath Gavin MacBeath Chief Executive Officer